Biden, Xi at loggerheads on Taiwan in lengthy virtual summit

Published by
AFP

Washington (AFP) – US President Joe Biden and China’s Xi Jinping traded strong warnings on the future of Taiwan at a virtual summit meant to establish “guardrails” against conflict between their rival superpowers. The video-link summit, which took place late Monday in Washington and early Tuesday in Beijing, lasted a “longer than expected” three and a half hours, a senior US official told reporters. “The conversation was respectful and straightforward.” While the goal was to settle an increasingly volatile relationship between the giant economic and geopolitical competitors, tension over Taiwa… Read more about Biden, Xi at loggerheads on Taiwan in lengthy virtual summit

Competition, not conflict: Biden, Xi call for more ‘communication and cooperation’

Published by
NJ.com

WASHINGTON — President Joe Biden and China’s Xi Jinping’s more than three-hour virtual talk concluded with the leaders of the superpowers agreeing they need to tread carefully as their nations find themselves in an increasingly fraught competition. Facing domestic pressures at home, both Biden and Xi seemed determined to lower the temperature in what for both sides is their most significant — and frequently turbulent — relationship on the global stage. “As I’ve said before, it seems to me our responsibility as leaders of China and the United States is to ensure that the competition between our… Read more about Competition, not conflict: Biden, Xi call for more ‘communication and cooperation’

Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Published by
ACN Newswire

Foster City, CA, Shanghai and Hangzhou, China, Nov 22, 2021 – (ACN Newswire) – Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the first patient has been successfully dosed in a Phase 3 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) in China. Apollomics licensed the Greater China rights for uproleselan from GlycoMimetics. “As our first Phase 3 clinical trial, dosing of the first patient wit… Read more about Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia